Digestive Diseases and Sciences

, Volume 43, Issue 5, pp 1009–1015 | Cite as

Comparative Study of Potential for Bisphosphonates to Damage Gastric Mucosa of Rats

  • C. P. Peter
  • M. V. Kindt
  • J. A. Majka
Article

Abstract

Bisphosphonates have generally few clinicaladverse effects, the most common being gastrointestinaldisturbances. It is generally believed thatbisphosphonates with a primary amine are more irritatingto the gastrointestinal tract than those withouta primary amine. The objective of this study was tocompare the gastric irritation potential of an aminobisphosphonate (alendronate) to that of two nonamino bisphosphonates (risedronate and etidronate) ina rat model at pharmacologically equivalent andclinically relevant doses. The doses used were 1, 5, 10,and 30 mg/kg/day for alendronate and risedronate and 40, 200, 400, and 1200 mg/kg/day foretidronate. These doses represent 5-150 times therecommended clinical dose. The drugs were given orally,daily by gavage for four weeks. The gastric irritation potential was assessed by gross and microscopicevaluation of multiple sections of the stomach. Thisstudy showed that, at pharmacologically equivalentdoses, the gastric irritation potential for alendronate is no greater than that for etidronate orrisedronate.

BISPHOSPHONATES GASTRIC IRRITATION 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Fleisch H: Bisphosphonates: History and expe rimental basis. Bone 8(suppl 1):23-28, 1987Google Scholar
  2. 2.
    Fleisch H: Bisphosphonates: Pharmacology and use in treatment of tumor-induced hypercalcemia and me tastatic bone disease. Drugs 42:919-944, 1991Google Scholar
  3. 3.
    Fleisch H: Bisphosphonates in bone disease Ð from the laboratory to the patient. New York, The Parthenon Group, 1997Google Scholar
  4. 4.
    Fleisch H: Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62, 1997Google Scholar
  5. 5.
    Chestnut CH, McClung MR, Ensrud KE, Be ll NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC: Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 29:144-152, 1995Google Scholar
  6. 6.
    Lufkin EG, Argue ta R, Whitaker MD, Cameron AL, Wong V, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 4:320-322, 1994Google Scholar
  7. 7.
    de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Fre edholm D, Pryor-Tollotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996Google Scholar
  8. 8.
    Saunders RL: Appearance of a gastric ulcer during diphosphonate therapy in a women with CRST syndrome. South Med J 70:1327-1329, 1977Google Scholar
  9. 9.
    Scurr JH, Cutting P: Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone disease s. Br Med J 288:828-829, 1984Google Scholar
  10. 10.
    Re ginster JYL: Oral tiludronate: Pharmacological properties and potential use fulness in Paget' s disease of bone and osteoporosis. Bone 13:351-354, 1992Google Scholar
  11. 11.
    Hannuniemi R, Lauren L, Puolijoki H: Clodronate: An e ffective agent for the treatment of increased bone resorption. Drugs Today 27:375-390, 1991Google Scholar
  12. 12.
    Pete r CP, Handt LK, Smith SM: Esophageal irritation due to alendronate sodium tablets: Possible me chanisms. Dig Dis Sci 1997 (in press)Google Scholar
  13. 13.
    Nixon GA, Buchle r EV, Neuman EA: Pre liminary safety asse ssment of disodium etidronate as an additive to experimental oral hygiene products. Toxicol Appl Pharmacol 22:661-671, 1972Google Scholar
  14. 14.
    Blank AM, Ems BL, Gibson GW, Myers WR, Berman K, Phipps RJ, Smith PN: Nonclinical mode l to asse ss gastric effects of bisphosphonate s. Dig Dis Sci 42:281-288, 1997Google Scholar
  15. 15.
    Wallace JL, McKnight W, Davies NM, Elliott SN: Alendronate, an osteoporosis drug, increases the incidence and severity of NSAID-induced ulcers in rabbits and rats. AGA Rese arch Forum Abstract, 1997 p A325Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • C. P. Peter
  • M. V. Kindt
  • J. A. Majka

There are no affiliations available

Personalised recommendations